2026-04-29T12:23:40Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/197382024-11-28T16:59:06Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16959
Repisalud
author
Barahona-López, Cristina
author
Plans-Beriso, Elena
author
Petrova, Dafina
author
Fernández-Martínez, Nicolás Francisco
author
Craciun, Oana Marilena
author
García-Ovejero, Ester
author
Arruabarrena, E
author
Hernández, Orlando
author
Diez-Echave, Paul
funder
Unión Europea. Comisión Europea. Horizonte Europa
funder
UK Research and Innovation
2024-06-11T10:06:47Z
2024-06-11T10:06:47Z
2023
Gac Sanit. 2023;37(S1):230-230.
Gac Sanit.
http://hdl.handle.net/20.500.12105/19738
Background/Objectives: One of the first steps of the PeRsOnalized Prevention roadmap for the future HEalThcare (PROPHET) project is to carry out several scoping reviews about research on biomarkers useful for personalized prevention -primary/secondary- of neurodegenerative diseases. Methods: A rapid scoping review was conducted (Feb-Jun 2023). Inclusion criteria were defined. Population: Adult general population (> 18 years), specific high-risk subgroups. Concept and context: Biomarkers that help to stratify the risk –either in primary or in secondary prevention– of amyotrophic lateral sclerosis, Parkinson disease, Alzheimer’s disease, frontotemporal dementia, vascular dementia, Lewy body disease and multiple sclerosis. We also included “cognitive decline” as a proxy of dementia. The literature available between 2020 and 2023 was reviewed using bibliographic bases, grey literature and expert consultation. Independent reviewers screened and extracted information from 10% of the papers, and the rest was screened by one reviewer –due to time constraints–. A graphical interactive map was created to visually identify the evidence gaps in the literature. Results: A total of 1,653 articles –after removing 395 duplicates– were obtained of which 28% (n = 460) were selected for the full-text phase. The most researched neurodegenerative disease was Alzheimer, followed by Parkinson, multiple sclerosis and amyotrophic lateral sclerosis. Regarding the type of biomarker, more than half of articles included genetic/epigenetic biomarkers, and one third integrated imaging techniques. Few articles used -omics-based biomarkers or utilized artificial intelligence and/or deep learning methods. The results were presented taking into account the general population versus the high-risk groups of population (smoking, alcohol consumption, diabetes, obesity, hypertension, hypercholesterolemia or dyslipidaemia) as well as the clinical utility of the biomarkers. Conclusions/Recommendations: In this scoping review we provide a general picture of the state of art in the use of biomarkers for neurodegenerative diseases, which will inform the future Strategic Research and Innovation Agenda (SRIA) for the European Union.
eng
PROPHET project
Biomarker
Cardiovascular Diseases
Amyotrophic lateral sclerosis
Parkinson disease
Alzheimer’s disease
Frontotemporal dementia
Vascular dementia
Lewy body disease
Multiple sclerosis
Neurodegenerative diseases: a rapid scoping review of biomarkers for personalized prevention
conference proceedings
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
URL
https://repisalud.isciii.es/bitstreams/401a9a82-e828-4572-bcb5-0c4a19e365ae/download
File
MD5
b60b216a4a042e74924a6fdbcd85aabc
442572
application/pdf
NeurodegenerativeDiseasesRapidScopingReview_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/2167aa62-a098-452a-9562-b919857d8ca6/download
File
MD5
fb2002787eb117a52cbea3fb7067a6e0
7516
text/plain
NeurodegenerativeDiseasesRapidScopingReview_2023.pdf.txt